Anti-NRP2 Antibody Compositions and Methods for Treating NRP2-Associated Diseases
Summary
The USPTO published patent application US20260092122A1 for affinity-matured and humanized antibodies targeting human neuropilin-2 (NRP2) polypeptides. The application (No. 19293892, filed August 7, 2025) names six inventors and covers therapeutic compositions and methods for modulating NRP2 activity to treat NRP2-associated diseases, including cancer (A61P 35/04).
What changed
The USPTO published a patent application for anti-NRP2 antibodies and antigen-binding fragments that specifically bind to human neuropilin-2 polypeptides and modulate binding interactions between NRP2 and its ligands, thereby affecting downstream signaling events. The application covers affinity-matured and humanized antibodies, related therapeutic compositions, and methods for treating diseases associated with NRP2 dysregulation.
This publication represents a pending patent application with no immediate compliance obligations for third parties. Pharmaceutical and biotechnology companies developing NRP2-targeted therapies should review the claims to assess potential freedom-to-operate implications or licensing opportunities. The application has no stated comment period or compliance deadline as it is a patent filing rather than a regulatory rulemaking.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIES
Application US20260092122A1 Kind: A1 Apr 02, 2026
Inventors
Luke BURMAN, Yeeting CHONG, Leslie Ann GREENE, David KING, Zhiwen XU, Ryan Andrew ADAMS
Abstract
Provided are affinity matured and humanized antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.
CPC Classifications
C07K 16/2863 A61K 39/3955 A61P 35/04 A61K 39/001103 A61K 2039/505 C07K 2317/24 C07K 2317/33 C07K 2317/52
Filing Date
2025-08-07
Application No.
19293892
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.